Introduction
FOXP3 (a forkhead transcription factor family member, implicated in T-cell regulation, activation and differentiation) is a nuclear protein thought to function as a transcriptional repressor and the role that it plays in self-tolerance has been studied in both mice and humans. 1 It has been demonstrated that the lack of a functional FOXP3 gene product leads to the defective production of regulatory T-cells (T reg ), a subpopulation of T cells specialized in maintaining the balance between immunity and tolerance, 2 resulting in the development of fatal autoimmune, allergic and inflammatory diseases. [3] [4] [5] Humans with defects in the FOXP3 gene, develop strong activation of the immune system, leading to multiorgan autoimmune disease, allergies, inflammatory bowel disease and severe infections, collectively known as the immune deregulation, polyendocrinopathy, enteropathy, X-linked inheritance syndrome (IPEX syndrome). 6 Interestingly, Scurfy mice, an Foxp3-mutant strain, succumb to similar X-linked recessive autoimmune/inflammatory disease as a results of massive lymphocytic infiltration and uncontrolled CD4 þ T-cell activation. 7 FOXP3 represents a new T-cell marker considered to be more specific for T reg cells than other markers such as GITR and CTLA-4 or the coexpression of CD4 and CD25. 3, [8] [9] [10] Interestingly, our studies on FOXP3 protein expression at the single cell level have confirmed that a small proportion of FOXP3 þ cells are CD8 þ and that FOXP3 expression is also present in a minority of CD25À T cells. 8 The CD4 þ /CD25 þ T reg cell subset have been shown to functionally regulate the immune response through the antigen-specific suppression of effector CD4 þ /CD25À and CD8 þ T cells. 8 Gene transfer of FOXP3 converts naïve CD4 þ CD25À T cells towards a regulatory phenotype in both mice and humans and thus this molecule represents a functionally important marker of this T reg -cell population. [9] [10] [11] These observations suggest that FOXP3 is currently the most definitive marker of T reg cells, and its detection could allow a better understanding of the mechanisms through which T reg cells are involved in autoimmune and infectious diseases, as well as transplantation and tumour immunity.
Human T-cell lymphotropic virus type I (HTLV-1) is a virus that is associated with a wide variety of human diseases including adult T-cell leukaemia, AIDS, neurological disorders, uveitis and arthropathy. This virus is highly endemic in southern Japan and the Caribbean basin and occurs sporadically in Africa, Latin America, the Middle East, and the US.
12,13 Adult T-cell leukaemia/lymphoma (ATLL), was the first human malignancy shown to be caused by a retrovirus (HTLV-1) and represents a lymphoproliferative disease of post-thymic T-cells, and usually presents a CD4 þ /CD25 þ phenotype.
14 In general, ATLL is an aggressive disease characterized by poor prognosis as a result of significant immune-suppression, resulting in severe infections and resistance to combination chemotherapy. However, ATLL patients can present different clinical features resulting in a division of the disease into four clinical subtypes: acute (leukemic ATLL with a median survival of 6 months), lymphoma type ATLL (characterized by lymphadenopathy with a median survival of 10 months), chronic ATLL and smouldering ATLL (median survival of more than 24 months). 15 Progression from the indolent to acute variants occurs in 25% of cases.
Usually, the diagnosis of ATLL is not problematical in endemic areas and is based on morphology and phenotype. The malignant cell population can be identified by the expression of T-cell markers (CD2, CD3, CD4 and CD5) and activation markers (HLA-DP, HLA-DQ, HLA-DR and the interleukin-2 receptor a chain). CD7 and CD8 antigens are usually absent. It is noteworthy that CD25 is also expressed in nearly all cases, suggesting a common T reg cell origin. 16 Moreover, recent studies have illustrated that FOXP3 expression may be an additional feature of some ATLL cases. 17 However, the diagnosis of ATLL and its distinction from other common peripheral T-cell lymphomas can be complicated, especially for the lymphomatous variants in nonendemic areas.
Owing to the importance of FOXP3 in the development and function of T reg cells, and its potential use as a specific T reg marker, we have developed several monoclonal antibodies against FOXP3, for use on paraffin-embedded tissue sections 8 and evaluated its expression in a large series of B-and T-cell lymphomas. The selective reactivity of anti-FOXP3 with approximately two thirds of paraffin-embedded ATLL samples makes this antibody a potentially useful diagnostic tool.
Materials and methods

Patient samples
Lymph node biopsies from 23 ATLL cases were provided by one of the authors (KO) and two cases where obtained from the tissue archives of the CNIO Tumour Bank. All these patients present with lymphoma type ATLL. HTLV-1 provirus integration was confirmed in all ATLL samples by ELISA and Southern-blot techniques. 18, 19 For comparison, we studied a large series of samples representing T-and B-cell neoplasms, including T-cell lymphoblastic lymphoma (four), peripheral T-cell lymphoma (20) , angioimmunoblastic T-cell lymphoma (five), T-cell/natural killer cell lymphoma (five), anaplastic large cell lymphoma (nine), mycosis fungoides (15), B-cell lymphocytic leukaemia/lymphoma (14) , mantle cell lymphoma (14) , marginal zone B-cell lymphoma (12) , diffuse large B-cell lymphoma (17) , follicular lymphoma (17) and Burkitt's lymphoma (15) . Informed consent was obtained from all patients included in the study under the supervision of the local ethical committees. Reactive (non-neoplastic) lymphoid tissues (five tonsillectomy specimens and five lymph nodes) were obtained from the CNIO tumour bank.
Tissue sections (2-4 mm) were cut onto Dako slides (DakoCytomation, Glostrup, Denmark), incubated at 601C overnight and deparaffinised twice, using xylene (10 min, room temperature). The slides were hydrated in a series of ethanol solutions (100, 95 and 75% for 5 min each) and washed with PBS.
Immunohistochemistry
The FOXP3 monoclonal antibody (clone 236A/E7) was produced in the monoclonal antibodies unit of the CNIO in collaboration with AHB, as previously described. 8 Immunohistochemistry on paraffin sections was performed using the pressure-cooking method of antigen retrieval (2 min, citrate buffer pH 6.5). 20 Before staining, endogenous peroxidase was blocked, the slides were incubated for 40 min with the primary antibody (dilution 1:2 in PBS) and washed with PBS. Immunodetection was performed with biotinylated anti-mouse secondary antibodies (25 min), followed by peroxidase-labelled streptavidin (LSAB-DAKO) (25 min) and diaminobenzidine chromogen as substrate. All immunostaining was performed using the Techmate 500 automatic immunostaining device and reagents supplied by DakoCytomation.
We have used the observed staining intensity for the scattered FOXP3-postive cells present in the reactive component as a threshold. Scoring of the cases by performed by JF Garcia and MA Piris.
Statistical analysis
Overall survival (OS) was calculated from the date of pathological diagnosis to death or to the last date of followup. Actuarial survival curves, in terms of OS, were estimated by the Kaplan-Meier method and statistical significance of difference between FOXP3-positive and -negative cases was evaluated using the log-rank test. Median OS was also compared with a one-factor ANOVA method. A P-value of 0.05 or less was considered statistically significant. The SPSS software package (SPSS Inc., Chicago, IL; 1999) was used for the analyses.
Results
FOXP3 expression in normal and tumoural samples
In reactive lymphoid tissue (five tonsils and five lymph nodes), strong nuclear FOXP3 expression was observed in approximately 5% of interfollicular T-cells (Figure 1a ). This FOXP3-positive population showed a heterogeneous morphology.
Results of the examination of FOXP3 protein expression in lymphomas are shown in Table 1 . In the 89 B-and 58 non-ATLL T-cell lymphomas, FOXP3 expression was only detected in the reactive T-cell component (Figure 1 ), without any noticeable (Figure 1b-d) staining in the tumoural cells. The proportion of FOXP3-positive reactive T-cells was highly variable, as compared with normal reactive tissue, ranging from almost a complete absence (usually seen in Burkitt's lymphoma, Figure 1d ) to an evident infiltrate (common in follicular lymphoma, Figure 1c) . In contrast, FOXP3 expression in the tumour cells was detected in 17/25 (68%) ATLL cases. In all these cases, FOXP3 expression was detected in CD4/CD25 positive cells (Figure 2 ) ( Table 2 ).
In terms of FOXP3 expression, three subgroups of ATLL cases could be defined taking into account both the proportion of positive cells and the intensity of the expression. The first subgroup (32% of patients) represents samples with strong nuclear FOXP3 expression in the majority of tumour cells (Figure 3a (Figure 3e) . Finally, the third group of cases (32% of patients) comprised ATLL samples where FOXP3 expression was clearly absent in the tumour cells (Figure 3f and g ).
Survival analysis
As has been commonly reported, the course of ATLL is generally rapidly progressive and ultimately fatal with only one of the patients remaining alive at the follow-up (OS ranging from 1 to 133 months). The analysis of the relationship between FOXP3 protein expression and survival only showed a near significant association with survival: patients with FOXP3-negative tumours tending to have better survival (median OS 41 months (range 1-133) vs 7 months (range 2-65); P ¼ 0.060) than those with strong or intermediate FOXP3 expression (Figure 4 ). There was no significant difference in OS between the groups with intermediate or strong FOXP3 expression.
Discussion
The availability of a FOXP3 monoclonal antibody, not only provides an important tool for the study of the development and function of T reg cells, 21 but also represents a useful marker for the identification of FOXP3-positive ATLL cases in formalinfixed paraffin-embedded tissue sections. Although this lymphoma type is endemic in restricted areas (such as south-western Japan, West Africa, and the Caribbean Islands), ATLL cases have The existence of a subset of FOXP3-negative ATLL cases, confirms the heterogeneity of ATLL cases in terms of pathological, biological and clinical features. ATLL is characterised by different clinical forms, 13 that could be related to changes in the phenotype of tumoural cells. Interestingly, murine antigen driven IL-10-secreting T reg cells have comparable function to naturally occurring CD4 þ /CD25 þ T reg cells but lack FOXP3 expression. 22 The identification of clinical, histopathological and biological features that are useful for distinguishing different risk groups is a relevant issue in the therapeutic management of these rare lymphomas. Our limited analyses show median OS of 7 and 41 months in the FOXP3-positive group and the FOXP3-negative group, respectively. These findings suggest that tumours with high FOXP3 expression may have a more aggressive clinical course. However, due to the rarity of these lymphomas imposing restrictions on the number of cases available, the statistical significance of these findings is inconclusive. The potential clinical relevance of this FOXP3 expression therefore needs to be explored in a larger series.
Interestingly, Matsubara et al 23 also found heterogeneous FOXP3 expression in 20 ATLL patients at the mRNA level, describing cases with low and intermediate FOXP3 expression, in agreement with our observations. They suggest that those cases expressing FOXP3 are likely to suppress immune response through the expression of CTLA-4 and in some cases with significant production of TGFb, supporting the hypothesis that FOXP3-positive ATLL could potentially modulate the immune FOXP3, a selective marker for a subset of ATLL G Roncador et al response against the tumour and to be directly implicated in the generation of the immunodeficiency state commonly associated with ATLL patients. 13, 24 In agreement with these suggestions, our results show that FOXP3-positive ATLL tend to have a worse prognosis. At this point, as with defining the clinical features of ATLL cases, a Although it is tempting to speculate that CD4 þ /CD25 þ T reg cells are the normal counterpart of ATLL, our data could support different interpretations. Matsubara et al suggest two possible mechanisms implicated in ATLL origin. In the first case CD4 þ /CD25 þ T reg cells could undergo malignant transformation after HTLV-1 infection. In this case, it is possible to speculate that ATLL could be derived from CD4 þ /CD25 þ T reg cells, which, as a result of tumour transformation, can induce changes in FOXP3 expression. In the second case, leukemic cells could originate after HTLV-1 transformation of CD4 þ / CD25À cells that could differentially regulate FOXP3 expression resulting in heterogeneous expression in ATLL cases, phenotypically and functionally resembling T reg cells. At the present time, it is unclear which of these two mechanisms is most active in the development of ATLL. 25 The identification and characterisation of FOXP3 target genes could clarify these controversial interpretations and may provide additional markers for the FOXP3-negative ATLL subgroup.
In other lymphoma types, FOXP3 expression is only detected in the reactive T-cell background, and the number of FOXP3-positive reactive T cells is variable, ranging from almost a complete absence (Burkitt's lymphoma) to an evident infiltrate (common in follicular lymphoma). Interestingly, a recent study in Hodgkin's lymphoma has described that the differential expression of FOXP3 in the reactive background, permitted the distinction between patients with significantly different survival outcomes, 26 and similar observations has been also described in nonlymphoid neoplasms. 27 These results support the hypothesis that the presence or absence of T reg cells in the tumour environment could play a role in the progression of tumours, thus implying additional value for the detection of this cell population through the identification of patients for therapeutic intervention targeting T reg . Kaplan-Meier analysis of overall survival (OS) in ATLL patients grouped according to the expression of FOXP3: shorter survival in the FOXP3-positive group than in the FOXP3-negative group.
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